You are here: Industry Insights > Covishield

News List

India likely to approve authorise COVID-19 vaccines in weeks expresspharma
December 09, 2020
Government has identified 300 million people, including healthcare workers, policemen, and citizens above the age of 50, who would be administered a vaccine on a priority basis.
Serum Institute applies for EUA for Covishield in India expresspharma
December 07, 2020
According to sources, this vaccine is logistically feasible for distribution in the country's both urban and rural parts as it can be stored at two to eight degrees Celsius.
DCGI finds no linkage between Covishield shot and volunteer’s adverse event during trial expresspharma
December 03, 2020
An expert committee recommended that compensation should not be paid to the subject or legal heir/nominee of the subject.
Experts question continuation of Covishield vaccine trials in India despite adverse event report expresspharma
December 01, 2020
Censure SII’s move to file a defamation suit on the participant who reported the adverse event, stating that it will discourage honest feedback from participants and dissuade people from participating in clinical trials.
Covishield should be available for public by April 2021: Adar Poonawalla expresspharma
November 20, 2020
SII to make about 10 crore doses per month from February, 30-40 crore doses of the vaccine will be available by the first quarter of 2021.
1600 participants enrolled for Phase III clinical trials of Covishield expresspharma
November 12, 2020
SII and ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country.
SII pauses trials of COVID-19 vaccine candidate Covishield in India expresspharma
September 23, 2020
The company took this step after the DCGI issued a show cause notice to the company for not informing it about AstraZeneca pausing the clinical trials of the vaccine candidate in other countries.
Patient activist groups express relief over pause of Covishield trials in India expresspharma
September 14, 2020
They call for more timely responses and accountability on part of both regulators and companies to ensure patient safety.

Previous page 1 2 3 4 5 Next page